MedPath

Neurotech International Advances NTI164 Drug Trials with Ethics Approval for Pharmacokinetic Study

• Neurotech International has secured ethics approval to commence a pharmacokinetic study of NTI164 in healthy adults, a crucial step for regulatory compliance. • The study will provide essential data on the drug's metabolism and excretion, supporting its development for neurological disorders. • This advancement marks significant progress in Neurotech's clinical trials and regulatory efforts for NTI164 in the U.S. and Australia.

Neurotech International Ltd. has announced that it has received ethics approval to begin a pharmacokinetic study of its NTI164 drug in healthy adults. This is a pivotal step towards regulatory compliance in both the U.S. and Australia, paving the way for further clinical trials.

Pharmacokinetic Study Details

The study is designed to gather critical data on the metabolism and excretion of NTI164. Understanding how the drug is processed by the body is essential for determining optimal dosing and predicting potential drug interactions. This data will be instrumental in supporting the drug's development for treating various neurological disorders.

Significance for Clinical Development

This pharmacokinetic study represents a significant milestone for Neurotech International. The data obtained will be used to refine the clinical trial design and inform regulatory submissions. With successful completion of this study, Neurotech is poised to advance NTI164 further into clinical development, potentially addressing unmet needs in the treatment of neurological conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Sen-Jam Pharmaceutical's SJP-001 Receives Ethics Approval for Clinical Trial in Australia

Sen-Jam Pharmaceutical's SJP-001, an over-the-counter therapeutic, has received ethics approval for a clinical trial in Australia.
The trial, conducted by Nucleus Network and supported by Novotech, will assess SJP-001's efficacy and safety in modulating inflammation and improving metabolic outcomes.

FDA Fast-Tracks NeuroVive's Traumatic Brain Injury Drug

The FDA has granted Fast Track designation to NeuroVive's drug, NeuroSTAT, aimed at treating moderate to severe traumatic brain injury (TBI). This status accelerates the drug's development and review process, offering more frequent FDA interactions and feedback. NeuroSTAT works by protecting mitochondria, aiming to prevent secondary brain damage post-TBI, with hopes of improving survival, quality of life, and neurological function. Early trials have shown promising results, including a 35% decrease in brain injury volume in experimental models.

Clearmind Medicine's CMND-100 Receives IRB Approval for AUD Clinical Trial at Yale

Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD).
The trial, to be conducted at Yale School of Medicine, will assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings.

Neurotech Receives Approval to Commence Human Pharmacokinetic Study of NTI164

Neurotech has received ethics approval to begin a human pharmacokinetic study of its drug NTI164 in Adelaide.
NTI164, an oral cannabinoid drug, is being developed for neurological disorders involving neuroinflammation.

Neurotech International's NTI164 Shows Promise in Pediatric Neurological Disorders

Neurotech International is progressing with trials of NTI164, a drug targeting pediatric neurological disorders, showing potential in improving neural network function.
The drug aims to modulate neuroinflammation and enhance neuroprotection, addressing critical unmet needs in conditions like Autism Spectrum Disorder and Cerebral Palsy.

NIH's TrialGPT AI Algorithm Streamlines Clinical Trial Matching

The NIH has developed TrialGPT, an AI algorithm designed to efficiently match patients to relevant clinical trials listed on ClinicalTrials.gov.
TrialGPT demonstrated accuracy comparable to human clinicians in assessing eligibility criteria, while reducing screening time by 40% in a pilot study.

Intellia's CRISPR Therapy Nexiguran Ziclumeran Shows Promise in ATTR Amyloidosis Phase 1 Trial

Intellia's nexiguran ziclumeran (nex-z) demonstrates rapid and durable TTR reduction in ATTR amyloidosis patients, suggesting potential disease modification after a single dose.
In ATTR-CM patients, nex-z shows stabilization or improvement in cardiac markers at 12 months, including NT-proBNP, hs-Troponin T, and 6-minute walk test.

Intellia's CRISPR Therapy Nexiguran Ziclumeran Shows Promise in ATTR Amyloidosis Phase 1 Trial

Intellia's nexiguran ziclumeran (nex-z) demonstrates rapid and durable TTR reduction in ATTR amyloidosis patients, suggesting potential for significant clinical benefit.
The Phase 1 trial reveals stabilization or improvement in cardiac markers for ATTR-CM patients and neuropathy measures for ATTRv-PN patients after nex-z treatment.

Tivic Health Completes Enrollment in Vagus Nerve Stimulation Trial

Tivic Health has finished enrolling participants in a study evaluating its non-invasive vagus nerve stimulation (VNS) system.
The Feinstein Institute is conducting the trial to optimize device parameters like frequency and duration for influencing the autonomic nervous system.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

Reference News

[1]
Neurotech International Advances NTI164 Drug Trials | Markets Insider
markets.businessinsider.com · Nov 25, 2024

Neurotech International Ltd. (AU:NTI) received ethics approval for a pharmacokinetic study of NTI164 in healthy adults, ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy